Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

E069 Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to Tumour Necrosis Factor Inhibitors Who Were Responders at Week 16: Results from a Phase 3, Randomised Study

William R Tillett,Joseph F Merola,Yoshiya Tanaka,Ennio G Favalli,Dennis McGonagle,Diamant Thaçi,Jessica A Walsh,Barbara Ink,Rajan Bajracharya,Jason Coarse,Christopher T Ritchlin

Rheumatology（2024）

Cited 0|Views18
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined